相关实验视频

Updated: Jul 25, 2025

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

瘤标记物及其在鼻ITAC/非ITAC中的预后价值

Julius Veuger¹, Nona C Kuipers^1,2, Stefan M Willems³

¹Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.

|June 28, 2023

概括

对鼻腔 (非肠道) 类型腺癌 (ITAC/非ITAC) 的预后生物标志物进行了审查. 一些生物标志物,包括mucin抗原sialosyl-Tn和TP53,表明这些罕见瘤的预后较差.

科学领域:

在瘤学瘤学.
病理学病理学病理学

背景情况:

鼻腔 (非肠道) 类型腺癌 (ITAC/非ITAC) 是一种罕见的瘤.
目前的治疗包括手术和放射治疗,并进行全身治疗以提供息治疗.
对ITAC/非ITAC的预后是非常可变的.

研究的目的:

为了确定鼻 (非) 的预后生物标志物.ITAC.
了解生物标志物在瘤发育中的作用,使用癌症特征.
帮助临床决策管理这些罕见的恶性瘤.

主要方法:

在PubMed数据库的系统文献搜索.
纳入研究调查预后生物标志物的研究,在sinonasal ITAC/non-ITAC.
在癌症的特征中对发现进行分类.

主要成果:

21项研究确定了21种潜在的预后生物标志物.
粘真菌抗原sialosyl-Tn,C-erbB-2上蛋白,TIMP3甲基化,TP53,VEGF,ANXA2,MUC1和粘真菌亚型对生存有负面影响.
没有生物标志物被发现具有积极的预后效应.

结论:

多种生物标志物与鼻 (非) ITAC 中的负面预后有关.
癌症的特征是"激活入侵和转移"和"维持增殖信号"是显著的.
对这些生物标志物的进一步研究可能会改善患者管理.

关键词:

(非) ITAC 的情况.生物标志物生物标志物预后预后预后鼻癌是一种鼻癌.幸存率幸存率生存率

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.